Perspective Therapeutics (CATX) Stifel 2024 Healthcare Conference summary

Industry landscape and radiopharma positioning

• Radiopharmaceuticals offer immediate tumor impact and the ability to both image and treat using the same molecule, enabling personalized therapy decisions.

• The sector is rapidly evolving, with differentiation driven by drug design, distribution, and proprietary IP.

• Radiopharma is positioned as a targeted therapy, complementing other modalities like ADCs and bispecifics, with unique advantages in treating tumors from the inside out.

Isotope and chelator innovation

• Lead-212 is favored for its dual diagnostic and therapeutic capabilities, short half-life, and potent alpha emissions, allowing for a rapid, focused therapeutic effect.

• Proprietary chelator technology minimizes off-target daughter isotope leakage (<2%), improving safety and biodistribution compared to generic chelators.

• Alignment of peptide targeting vectors with short-lived isotopes enables rapid tumor targeting and clearance, reducing systemic exposure and off-target effects.

Manufacturing, logistics, and supply chain

• Distributed manufacturing network established across the US (West Coast, Midwest, East Coast, Texas) to support just-in-time delivery for short shelf-life products.

• Focused on supplying cancer care centers, leveraging experience with products requiring rapid distribution and administration.